Xintian Pharma

Xintian Pharma’s stock price has surged 10.03% to 10.87 CNY, driven by strong investor confidence and a net inflow of 81.93 million CNY, as the company navigates market challenges and capitalizes on favorable sector trends.

Xintian Pharma’s financial performance declined in the first half of 2025, with revenue and net profit down 18.88% and 80.99% year-over-year, respectively.